PT2297152E - Forma cristalina anidra de maleato de orvepitanto - Google Patents

Forma cristalina anidra de maleato de orvepitanto Download PDF

Info

Publication number
PT2297152E
PT2297152E PT9731234T PT09731234T PT2297152E PT 2297152 E PT2297152 E PT 2297152E PT 9731234 T PT9731234 T PT 9731234T PT 09731234 T PT09731234 T PT 09731234T PT 2297152 E PT2297152 E PT 2297152E
Authority
PT
Portugal
Prior art keywords
crystal form
anhydrous crystal
orvepitant maleate
orvepitant
maleate
Prior art date
Application number
PT9731234T
Other languages
English (en)
Inventor
Beato Stefania
Franco Sartor
Ian Philip Steeples
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of PT2297152E publication Critical patent/PT2297152E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
PT9731234T 2008-04-11 2009-04-09 Forma cristalina anidra de maleato de orvepitanto PT2297152E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0806652.4A GB0806652D0 (en) 2008-04-11 2008-04-11 Anhydrous crystal form of orvepitant maleate

Publications (1)

Publication Number Publication Date
PT2297152E true PT2297152E (pt) 2015-02-16

Family

ID=39433527

Family Applications (1)

Application Number Title Priority Date Filing Date
PT9731234T PT2297152E (pt) 2008-04-11 2009-04-09 Forma cristalina anidra de maleato de orvepitanto

Country Status (27)

Country Link
US (1) US8309553B2 (pt)
EP (1) EP2297152B1 (pt)
JP (2) JP5875863B2 (pt)
KR (1) KR20110002090A (pt)
CN (1) CN102066376B (pt)
AR (1) AR071311A1 (pt)
AU (1) AU2009235440B2 (pt)
BR (1) BRPI0911678B8 (pt)
CA (1) CA2721119C (pt)
CL (1) CL2009000876A1 (pt)
CY (1) CY1115961T1 (pt)
DK (1) DK2297152T3 (pt)
EA (1) EA017082B1 (pt)
ES (1) ES2529295T3 (pt)
GB (1) GB0806652D0 (pt)
HR (1) HRP20141196T1 (pt)
IL (1) IL208597A0 (pt)
MX (1) MX2010011152A (pt)
PE (1) PE20091839A1 (pt)
PL (1) PL2297152T3 (pt)
PT (1) PT2297152E (pt)
RS (1) RS53732B1 (pt)
SI (1) SI2297152T1 (pt)
TW (1) TW201002714A (pt)
UY (1) UY31758A (pt)
WO (1) WO2009124996A1 (pt)
ZA (1) ZA201007120B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101842133B (zh) * 2007-10-30 2013-03-20 伊利克塔股份有限公司 放射治疗仪
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
WO2014057003A1 (en) 2012-10-11 2014-04-17 Nerre Therapeutics Limited Novel uses
JP6621534B2 (ja) * 2016-01-08 2019-12-18 ネッレ セラピューティクス リミテッドNerre Therapeutics Limited 慢性咳の処置のためのオルブピタント
BR112019021125A2 (pt) 2017-04-10 2020-05-12 Chase Therapeutics Corporation Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
CN111372934B (zh) 2017-08-18 2024-04-26 科瑞华生物技术有限公司 Tg02的多晶型形式
MX2022011545A (es) * 2020-04-03 2022-11-09 Nerre Therapeutics Ltd Un antagonista de receptor de nk-1 para tratar una enfermedad que se selecciona de sepsis, choque septico, síndrome de dificultad respiratoria aguda (ards) 0 síndrome de disfunción orgánica múltiple (mcds).
CN115697332A (zh) 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
BRPI0712014A2 (pt) 2006-05-22 2011-12-27 Vanda Pharmaceuticals Inc tratamento de distérbios depressivos
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
CN101918746A (zh) * 2007-11-02 2010-12-15 诚实公司 无o形圈密封联接件
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate

Also Published As

Publication number Publication date
TW201002714A (en) 2010-01-16
RS53732B1 (en) 2015-06-30
AU2009235440B2 (en) 2012-06-14
HRP20141196T1 (hr) 2015-02-13
EA201071183A1 (ru) 2011-06-30
EP2297152B1 (en) 2014-11-12
KR20110002090A (ko) 2011-01-06
BRPI0911678A2 (pt) 2015-10-13
US20110166150A1 (en) 2011-07-07
US8309553B2 (en) 2012-11-13
UY31758A (es) 2009-11-10
GB0806652D0 (en) 2008-05-14
JP2011516532A (ja) 2011-05-26
CA2721119C (en) 2016-04-05
BRPI0911678B8 (pt) 2021-05-25
JP2014205688A (ja) 2014-10-30
IL208597A0 (en) 2010-12-30
CN102066376B (zh) 2014-01-01
DK2297152T3 (da) 2015-01-26
EP2297152A1 (en) 2011-03-23
ZA201007120B (en) 2011-11-30
AR071311A1 (es) 2010-06-09
ES2529295T3 (es) 2015-02-18
WO2009124996A1 (en) 2009-10-15
MX2010011152A (es) 2010-12-21
EA017082B1 (ru) 2012-09-28
CN102066376A (zh) 2011-05-18
CY1115961T1 (el) 2017-01-25
SI2297152T1 (sl) 2015-02-27
CA2721119A1 (en) 2009-10-15
PE20091839A1 (es) 2010-01-07
AU2009235440A1 (en) 2009-10-15
BRPI0911678B1 (pt) 2021-03-02
PL2297152T3 (pl) 2015-04-30
CL2009000876A1 (es) 2010-05-14
JP5875863B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
HUS1800015I1 (hu) Kristályok
IL208597A0 (en) Anhydrous crystal form of orvepitant maleate
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
ZA201006754B (en) Crystal of benzimidazole compound
HK1160925A1 (zh) 組織蛋白酶 的用途
GB0813840D0 (en) Improved liquid crystal compounds
GB0908006D0 (en) New crystal form
GB0822248D0 (en) Crystal meths
EP2285776A4 (en) STABILIZATION OF TRIPHENYLBORE-PYRIDINE
EP2132171A4 (en) NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES
GB0806103D0 (en) Improvements to viewing devices
IL189405A0 (en) Stabilization of siva2
ZA201100141B (en) Stable crystal modifications of dopc
IL211688A0 (en) Novel crystal form of calcium 3-acetylaminopropane-1-sulfonate
GB2457157B (en) Crystal unit
TWM347258U (en) Structure of chisel
GB0811620D0 (en) Crystal structure